Merck (NYSE: MRK) which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc. (NYSE ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Merck (MRK) Reports Update on KEYNOTE-240, a Phase 3 Study of KEYTRUDA (pembrolizumab) in Previously Treated Patients with Advanced Hepatocellular CarcinomaFebruary 19, 2019 4:59 PM UPDATE: Pfizer (PFE) to Provide $15M Milestone Payment to Gliknik Inc. Following Clinical Progress with PF-06755347, Previously Known As GL-2045February 19, 2019 8:32 AM Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of MedicineFebruary 16, 2019 5:14 PM Merck (MRK) call put ratio 15 calls to 1 put with focus on expiring February 80 callsFebruary 15, 2019 12:37 PM Merck (MRK) Says FDA Granted Priority Review to its sBLA for KEYTRUDA in Combination with Inlyta as First-Line Treatment for Advanced RCCFebruary 15, 2019 6:46 AM Cerecor (CERC) Announces CERC-301 Granted U.S. PatentFebruary 15, 2019 6:34 AM